Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Baron Health Care Fund Neal Kaufman | “Arcellx, Inc. is developing cell therapies for multiple myeloma, including lead candidate anito-cel in partnership with Gilead. Anito-cel is a BCMA-targeted CAR-T therapy showing comparable efficacy with a more benign neurological side-effect profile relative to competitors. Despite encouraging clinical results, the stock detracted from performance following competitive data from Johnson & Johnson. Based on discussions with myeloma specialists, BCMA CAR-T is expected to remain the preferred second-line treatment for many patients. We continue to believe Arcellx's therapy is meaningfully differentiated on safety and expect shares to appreciate ahead of a potential 2026 launch. BSD Analysis: Arcellx is one of the more interesting next-gen CAR-T stories because it's trying to fix what's broken, not repeat what already exists. Its cell therapy approach focuses on improved safety, durability, and manufacturability — the real bottlenecks in CAR-T adoption. Early data has been encouraging, but oncology optimism is always fragile. Partnerships with large pharma help de-risk development but don't eliminate binary outcomes. Commercial success depends on differentiation, not just approval. Cash burn is real, and timelines are long. This is not a platform company yet. It's a precision bet on better cell therapy execution. High risk, but not unserious.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.